Pegfilgrastim Dosing (per Label)

ورودی‌های بالینی بیمار

حداقل ۲ — حداکثر ۲۰۰ • واحد: kg

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
dose mg
—mg
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Dosed≥ 0
Direct Clinical Answer

The Pegfilgrastim Dosing (per Label) calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include patient type. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Pegfilgrastim (Neulasta) dosing per FDA label: adults 6 mg SC once per chemotherapy cycle, ≥24 hours after cytotoxic chemotherapy and ≥14 days before the next cycle. Pediatric weight bands: <10 kg 0.1 mg/kg, 10-20 kg 1.5 mg, 21-30 kg 2.5 mg, 31-44 kg 4 mg, ≥45 kg 6 mg.

Clinical Indication

The Pegfilgrastim Dosing (per Label) is indicated for bedside clinical practice to support Pegfilgrastim (Neulasta) dosing per FDA label: adults 6 mg SC once per chemotherapy cycle, ≥24 hours after cytotoxic chemotherapy and ≥14 days before the next cycle. Pediatric weight bands: <10 kg 0.1 mg/kg, 10-20 kg 1.5 mg, 21-30 kg 2.5 mg, 31-44 kg 4 mg, ≥45 kg 6 mg.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.

Formula & Variables:

Adult: fixed 6 mg. Pediatric: weight-band dosing per label.

Input Parameters

NameTypeRequiredDescription
patient_typestringYesPatient type
weight_kgfloatNoWeight (pediatric only, kg)(kg)

Score Interpretation & Guidance

RangeStageDescription
≥ 0DosedPegfilgrastim dose

Evidence-Based References (EBM)

  • Neulasta (pegfilgrastim) FDA Prescribing Information. Amgen Inc. Dosage: 6 mg subcutaneously once per chemotherapy cycle; pediatric weight-based dosing as labeled.

Related calculators